University of Utah researchers have identified a protein, EFHD1, that appears to drive metabolic liver disease by triggering an out-of-place antiviral immune response. By blocking the protein in human cells and mouse models, scientists reduced inflammation and liver scarring by roughly 30 to 60 percent, paving the way for targeted new therapies.
Obesity-related metabolic liver disease affects hundreds of millions of people worldwide, yet only a fraction of those affected livers progress to severe inflammation, scarring, and eventual failure. A research team at the University of Utah has now pinpointed a specific cellular culprit that appears to govern that dangerous transition. Rather than acting directly on lipid metabolism—the traditional focus of most metabolic liver treatments—the protein EFHD1 hijacks cellular machinery to provoke an out-of-place immune reaction.
The study, published in the Journal of Clinical Investigation, was led by first author David Eberhardt, PhD, postdoctoral associate in internal medicine, and Dipayan Chaudhuri, MD, PhD, a cardiologist and associate professor of internal medicine at University of Utah Health. By demonstrating that genetic or pharmacological intervention against this protein can shield liver tissue from injury, the findings open a distinct therapeutic avenue for patients who experience only partial benefits from existing medications.
How a Mitochondrial Protein Triggers a False Viral Alarm
Dr. Chaudhuri’s laboratory previously linked EFHD1 to heart attack-like injuries in mice, while other scientific groups noted that genetic variants increasing EFHD1 activity correlated with human liver injury rather than simple fat accumulation. To understand the mechanism, the research team examined genetically engineered mice lacking the protein. In mice without EFHD1, mitochondria appeared stretched into long, spaghetti-like strands because they lacked the regular division promoted by EFHD1.
When mice consume a high-fat, high-sugar diet that induces liver injury, excess lipids drive up EFHD1 levels. This surplus drives excessive mitochondrial division, causing the organelles to leak their contents into the surrounding cell cytoplasm. Among the leaked material is double-stranded RNA—a signature normally associated with viral infections such as hepatitis C. Upon detecting this mitochondrial RNA, the cell mistakes its own internal stress for a pathogen invasion.
That mistaken antiviral defense strategy, meant to halt viral replication in infected tissue, instead shuts down healthy but stressed liver cells and accelerates tissue damage. The researchers emphasize that fat accumulation alone does not dictate the threshold for injury. The amount of lipid itself is not the only factor causing injury—that threshold varies a lot,
Dr. Chaudhuri noted, adding that shifting focus toward cellular injury pathways should yield just as much benefit.
Measurable Protection in Preclinical Models and Human Organoids
To test whether blocking the pathway could reverse or prevent damage, the investigators evaluated models where EFHD1 levels were reduced or completely eliminated. Across diet-induced mouse models, drug-induced liver injury models, and human liver organoids, measures of inflammation and liver scarring dropped by roughly 30 to 60 percent.
.jpg "Photo: Cuanschutz")
Current pharmaceutical options for obesity-related metabolic liver disease focus heavily on lipid metabolism and frequently provide only partial relief. Because EFHD1 operates through an entirely separate pathway, researchers view it as a complementary target for combination treatments. Reassuringly, mice bred without the protein maintained normal activity levels, standard weight gain, and typical metabolic markers, indicating that targeted therapies blocking EFHD1 may carry a favorable side-effect profile.
The university has already filed a patent covering aspects of the work as the research team pursues clinical translation. Beyond metabolic liver disease, the investigators plan to explore whether identical EFHD1-driven pathways cause injury in heart conditions and other metabolic disorders, as well as whether the mechanism contributes to alcohol-related liver damage.
Broader Implications Across Metabolic and Addictive Disorders
The discovery arrives alongside parallel investigations into how metabolic pathways intersect with liver pathology and addiction. Researchers at the University of Colorado Anschutz Medical Campus recently reported in Nature Metabolism that alcohol consumption triggers internal fructose production via the enzyme ketohexokinase (KHK), driving both alcohol-seeking behavior and liver scarring. While the University of Utah team targeted mitochondrial architecture and antiviral signaling, both lines of research highlight how specific enzymatic and molecular switches exacerbate organ damage independently of simple caloric intake.
Similarly, investigators at the David Geffen School of Medicine demonstrated that blocking the mitochondrial protein ABCB10 protects against high blood sugar and fatty liver disease in obese mice by modulating mitochondrial bilirubin synthesis. Together, these complementary discoveries underscore a broader shift in hepatology: moving beyond broad lifestyle advisories and lipid management to pinpoint the exact intracellular triggers that turn metabolic stress into irreversible organ scarring.
